Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Benson, Edagwa"'
Autor:
Emma G. Foster, Brady Sillman, Yutong Liu, Micah Summerlin, Vikas Kumar, Balasrinivasa R. Sajja, Adam R. Cassidy, Benson Edagwa, Howard E. Gendelman, Aditya N. Bade
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2023)
The World Health Organization has recommended dolutegravir (DTG) as a preferred first-line treatment for treatment naive and experienced people living with human immunodeficiency virus type one (PLWHIV). Based on these recommendations 15 million PLWH
Externí odkaz:
https://doaj.org/article/ba6d4ed836814c72aee66959707f131a
Autor:
Mohammad Ullah Nayan, Sudipta Panja, Ashrafi Sultana, Lubaba A. Zaman, Lalitkumar K. Vora, Brady Sillman, Howard E. Gendelman, Benson Edagwa
Publikováno v:
Pharmaceutics, Vol 16, Iss 2, p 183 (2024)
The success of long-acting (LA) drug delivery systems (DDSs) is linked to their biocompatible polymers. These are used for extended therapeutic release. For treatment or prevention of human immune deficiency virus type one (HIV-1) infection, LA DDSs
Externí odkaz:
https://doaj.org/article/801fbe43738b4fdabac519e7aedc77ff
Autor:
Suyash Deodhar, Brady Sillman, Aditya N. Bade, Sean N. Avedissian, Anthony T. Podany, JoEllyn M. McMillan, Nagsen Gautam, Brandon Hanson, Bhagya L. Dyavar Shetty, Adam Szlachetka, Morgan Johnston, Michellie Thurman, Daniel J. Munt, Alekha K. Dash, Milica Markovic, Arik Dahan, Yazen Alnouti, Alborz Yazdi, Bhavesh D. Kevadiya, Siddappa N. Byrareddy, Samuel M. Cohen, Benson Edagwa, Howard E. Gendelman
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-15 (2022)
Here, using animal models, Deodhar et al. single parenteral dose of dolutegravir (DTG) prodrug nanocrystals sustains drug protein-adjusted 90% inhibitory concentration for up to a year, without injection site reactions or systemic toxicities.
Externí odkaz:
https://doaj.org/article/0e6c6ddce7834d67b915c46f752da67f
Autor:
Vicente Soriano, Carmen Alvarez, Benson Edagwa, Carmen de Mendoza, Noemí Montoya, Ana Treviño, Howard Gendelman
Publikováno v:
International Journal of Infectious Diseases, Vol 114, Iss , Pp 45-50 (2022)
ABSTRACT: Viral hepatitis is among the top four causes of mortality globally, causing 1.4 million deaths each year, exceeding tuberculosis, malaria and human immunodeficiency virus. Hepatitis B and C are responsible for 90% of hepatitis deaths, and t
Externí odkaz:
https://doaj.org/article/bc931963630446449087c7ae877d23df
Autor:
Emma G. Foster, Nicholas Y. Palermo, Yutong Liu, Benson Edagwa, Howard E. Gendelman, Aditya N. Bade
Publikováno v:
Frontiers in Toxicology, Vol 5 (2023)
More than fifteen million women with the human immunodeficiency virus type-1 (HIV-1) infection are of childbearing age world-wide. Due to improved and affordable access to antiretroviral therapy (ART), the number of in utero antiretroviral drug (ARV)
Externí odkaz:
https://doaj.org/article/b9159025b308451580c072153a6e3201
Autor:
Denise A. Cobb, Nathan Smith, Suyash Deodhar, Aditya N. Bade, Nagsen Gautam, Bhagya Laxmi Dyavar Shetty, JoEllyn McMillan, Yazen Alnouti, Samuel M. Cohen, Howard E. Gendelman, Benson Edagwa
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-16 (2021)
Antiretroviral therapy (ART) for the treatment of HIV-1 requires life-long daily adherence to supress viral replication, and nucleoside reverse transcriptase inhibitors that are commonly used in ART have not been converted into long-acting agents. He
Externí odkaz:
https://doaj.org/article/e78ef827a6654617b246aed85af2acee
Autor:
Prasanta K. Dash, Santhi Gorantla, Larisa Poluektova, Mahmudul Hasan, Emiko Waight, Chen Zhang, Milica Markovic, Benson Edagwa, Jatin Machhi, Katherine E. Olson, Xinglong Wang, R. Lee Mosley, Bhavesh Kevadiya, Howard E. Gendelman
Publikováno v:
Retrovirology, Vol 18, Iss 1, Pp 1-17 (2021)
Abstract Humanized mice model human disease and as such are used commonly for research studies of infectious, degenerative and cancer disorders. Recent models also reflect hematopoiesis, natural immunity, neurobiology, and molecular pathways that inf
Externí odkaz:
https://doaj.org/article/46c593d596184bbc8124e681560d5034
Autor:
Prasanta K. Dash, Rafal Kaminski, Ramona Bella, Hang Su, Saumi Mathews, Taha M. Ahooyi, Chen Chen, Pietro Mancuso, Rahsan Sariyer, Pasquale Ferrante, Martina Donadoni, Jake A. Robinson, Brady Sillman, Zhiyi Lin, James R. Hilaire, Mary Banoub, Monalisha Elango, Nagsen Gautam, R. Lee Mosley, Larisa Y. Poluektova, JoEllyn McMillan, Aditya N. Bade, Santhi Gorantla, Ilker K. Sariyer, Tricia H. Burdo, Won-Bin Young, Shohreh Amini, Jennifer Gordon, Jeffrey M. Jacobson, Benson Edagwa, Kamel Khalili, Howard E. Gendelman
Publikováno v:
Nature Communications, Vol 10, Iss 1, Pp 1-20 (2019)
Here, the authors show that sequential treatment with long-acting slow-effective release ART and AAV9- based delivery of CRISPR-Cas9 results in undetectable levels of virus and integrated DNA in a subset of humanized HIV-1 infected mice. This proof-o
Externí odkaz:
https://doaj.org/article/ad4b010214414d8c84777d8ae90f684b
Autor:
Brady Sillman, Aditya N. Bade, Prasanta K. Dash, Biju Bhargavan, Ted Kocher, Saumi Mathews, Hang Su, Georgette D. Kanmogne, Larisa Y. Poluektova, Santhi Gorantla, JoEllyn McMillan, Nagsen Gautam, Yazen Alnouti, Benson Edagwa, Howard E. Gendelman
Publikováno v:
Nature Communications, Vol 9, Iss 1, Pp 1-14 (2018)
Current ART for treatment of HIV-1 infection requires a strict daily regimen adherence. Herein, the authors report the manufacture and characterization of a nanoformulated dolutegravir prodrug with improved cell and tissue penetration, a remarkable a
Externí odkaz:
https://doaj.org/article/9fe938444e464eaea1e85845549ff241
Autor:
Prasanta K. Dash, Chen Chen, Rafal Kaminski, Hang Su, Pietro Mancuso, Brady Sillman, Chen Zhang, Shuren Liao, Sruthi Sravanam, Hong Liu, Emiko Waight, Lili Guo, Saumi Mathews, Rahsan Sariyer, R. Lee Mosley, Larisa Y. Poluektova, Maurizio Caocci, Shohreh Amini, Santhi Gorantla, Tricia H. Burdo, Benson Edagwa, Howard E. Gendelman, Kamel Khalili
Publikováno v:
Proceedings of the National Academy of Sciences. 120
Treatment of HIV-1 ADA -infected CD34+ NSG-humanized mice with long-acting ester prodrugs of cabotegravir, lamivudine, and abacavir in combination with native rilpivirine was followed by dual CRISPR-Cas9 C-C chemokine receptor type five (CCR5) and HI
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0521cb8aacc7a64087afd83a552e4482
https://doi.org/10.1073/pnas.2217887120
https://doi.org/10.1073/pnas.2217887120